This site contains promotional content intended for UK Healthcare Professionals and other relevant decision makers | Not a HCP? Visit our  Public Site.

Adverse Event reporting can be found at the bottom of the page | Prescribing Information for the relevant medicine can be found adjacent to the below content and/or in the footer below. 

Cardiovascular
Cardiovascular
Womens Health
Women's Health
two kidneys
Nephrology
Oncology
Oncology
Ophthalmology
Ophthalmology
Respiratory
Respiratory
Bayer for ProfessionalsYour Resource Portal

Latest resources

View more
Real World Experience
Practical insights into the experiences of clinicians implementing treatment with EYLEA® (aflibercept) 8 mg in the UK
PP-EYL-GB-3012, October 2025
Kerendia®▼(finerenone) Patient Support Materials
Access useful, downloadable resources for patients
RP-KER-GB-1189, October 2025
Navigating ATTR-CM Diagnosis
Beyonttra®▼ (acoramidis) | Explore resources on Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
PP-PF-CAR-GB-0060, October 2025
Ophthalmology Resources
Access useful, downloadable ophthalmology resources
PP-EYL-GB-2954, September 2025

Events & webinars

View more
Kerendia®▼ (finerenone) Short Videos
PP-KER-GB-0566, March 2024
Resources to support prostate cancer patients
A focus on drug-to-drug interactions, managing risk and navigating around psychosexual health.
PP-NUB-GB-2385, June 2025
Exploring the mHSPC Patient Journey
Join experts for evidence-based treatment strategies on the application of triple therapy in mHSPC.
PP-NUB-GB-2382, June 2025
Finding consensus on utilising triplet therapy in mHSPC p...
Discussing triplet therapy in low-burden metastatic hormone-sensitive prostate cancer (mHSPC).
PP-NUB-GB-2383, June 2025

Learning Zone

View more
Request An Interactive Pharmacist’s Guide
NUBEQA® (darolutamide)
PP-NUB-GB-2388, May 2025
NUBEQA® (darolutamide) Drug-Drug Interactions Learning Guide
PP-NUB-GB-2129, March 2025
Urogenital Symptoms and Sexual Difficulties
(5 mins) Often underreported and undertreated symptoms that significantly affect a woman's relationships.
PP-PF-WHC-IUS-GB-0085 October 2024
Musculoskeletal Symptoms, Anxiety, Low Mood and Brain Fog
(4 mins) Causes for musculoskeletal (MSK) symptoms, how menopause can worsen existing anxiety and depression.
PP-PF-WHC-IUS-GB-0084 October 2024

Podcasts

View more
Bonus Episode
with All Speakers
PP-EYL-GB-2553, December 2024
Drying Effects of EYLEA® (aflibercept) 8 mg
with Hani Hasan, Rossella Anzidei and Richard Gale
PP-EYL-GB-2552, December 2024
The Importance of Clinical Audits
with Hani Hasan
PP-EYL-GB-2551, December 2024
Practicalities of Using EYLEA® (aflibercept) 8 mg in Rout...
with Bhavin Maru
PP-EYL-GB-2550, January 2025

Products

View more
NUBEQA® (darolutamide)
About NUBEQA
PP-NUB-GB-2538, August 2025
Beyonttra®▼ (acoramidis) - Overview
About Beyonttra
PP-BEY-GB-0001, May 2025
EYLEA® (aflibercept) 2 mg
Discover data and resources about EYLEA 2 mg
PP-EYL-GB-2793, March 2025
EYLEA® (aflibercept) 8 mg
Discover data and resources about EYLEA 8 mg
PP-EYL-GB-2911, July 2025

Register with BayerPRO

To access additional resources, personalise your experience and keep up to date via electronic communications from Bayer.